IL6 and triple-negative breast carcinoma: The activation of this pathway further triggers the non-classical NF-κB signaling pathway, leading to the release of IL-6 and activating the IL-6/STAT3 signaling pathway, ultimately promoting the survival and development of drug resistance of triple-negative breast cancer cells (68).